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Abstract  
 The double membrane cell envelope of Gram negative bacteria is a sophisticated 
barrier that facilitates the uptake of nutrients and protects the organism from toxic 
compounds. An antibiotic molecule must find its way through the negatively charged 
lipopolysaccharide layer on the outer surface, pass through either a porin or the hydrophobic 
layer of the outer membrane, then traverse the hydrophilic peptidoglycan layer only to find 
another hydrophobic lipid bilayer before it finally enters the cytoplasm, where it typically finds 
its target. This complex uptake pathway with very different physico-chemical properties is 
one reason that Gram-negatives are intrinsically protected against multiple classes of 
antibiotic-like molecules, and is likely the main reason that in vitro target based screening 
programmes have failed to deliver novel antibiotics for these organisms. Due to the lack of 
general methods available for quantifying the flux of drugs into the cell, little is known about 
permeation rates, transport pathways and accumulation at the target sites for particular 
molecules. Here we summarise the current tools available for measuring antibiotic uptake 
across the different compartments of Gram-negative bacteria.  
Keywords: porins, outer membrane proteins, envelope permeability, efflux, antibiotic 
resistance, label-free, mass spectrometry, fluorescence, electrophysiology 
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Antimicrobial failure and resistance is now widely recognised across the scientific community 
as a major threat to the modern medical system1,2. A combination of significant drug 
discovery challenges3, poor economic incentivisation1,4 and frankly disastrous misuse in both 
medicine5 and particularly in agriculture6 has led us to the present scenario in which multi-, 
extreme- and now pan-drug resistant pathogens are leading to patient hospitalisations and 
mortalities across the globe7,8. There is a dire need to refresh the antibiotic pipeline with new 
drugs, with new modalities of action, in order to address the current lack of treatment options 
for these infections. 
 
To tackle the Worldwide problem of antibiotic resistance, the European Union currently 
supports a platform called New Drugs for Bad Bugs (ND4BB, www.ND4BB.eu), which is a 
broad series of public-private partnerships under the umbrella of the Innovative Medicines 
Initiative (see IMI, www.imi.europa.eu). A particular bottleneck in the development of new 
antibiotics is their poor permeability in Gram-negative bacteria, which therefore require high 
drug doses which in turn lead to toxic side effects1,9–11. The IMI sub-project Translocation in 
particular has focussed on the permeability challenge, with a report on their results due to be 
published soon9. Along the same lines, the US-based PEW foundation also recognises low 
permeability as a major bottleneck, and has a stated goal to “understand and overcome 
barriers to drug penetration and efflux avoidance for Gram-negative bacteria” (The PEW 
Charitable Trusts: The PEW Roadmap12).  
 
The low drug permeability of Gram-negatives arises due to their complex double membrane 
cellular envelope10,13–15, depicted schematically in Figure 116. To reach their (typically) 
cytoplasmic targets, small molecule antibiotics need to first traverse the outer membrane, 
which is an asymmetric bilayer containing a lipopolysaccharide (LPS) polymer network on its 
outer surface. This polymer mesh is a formidable permeability barrier to large molecules 
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irrespective of whether they are hydrophobic or hydrophilic. On the other hand, smaller 
solutes like nutrients or antibiotics depend on their ability to translocate through 
transmembrane -barrel proteins, known as porins13,17,18, to penetrate the hydrophobic outer 
membrane. It is also well established that the water-filled porins are typically selective for 
hydrophilic molecules. If the target is cytoplasmic, the therapeutic molecule next has to 
traverse the cytoplasmic membrane, a phospholipid bilayer that favours the transport of 
small hydrophobic molecules via solubility-diffusion mechanisms19,20. It is this dual entry 
barrier that underpins the ability of Gram-negatives to survive antibiotics and drug-like 
molecules that might otherwise be active against Gram-positive bacteria. In addition, Gram-
negatives also have in-built mechanisms for expelling toxic compounds from their interiors – 
these so called efflux pumps actively recognise and expel antibiotics and other toxins from 
the cell21–24. The net result of this is that pharmaceutical in vitro target based screening 
programmes routinely struggled to deliver an agent active against Gram-negatives, simply 
because the candidates failed to accumulate in the vicinity of their targets at lethal 
concentrations. There is thus a very limited subset of molecules capable of breaching Gram-
negative permeability barriers and, with the inexorable spreading of resistant strains, we are 
running out of treatment options at an alarming rate.   
 
Despite the obvious importance of this problem and decades of work, the permeability 
issues associated with Gram-negative cell envelopes have remained challenging to 
overcome; we still lack a fundamental understanding of the rules governing molecular 
transport across these membranes. Early work using radioactive tracer molecules revealed 
selective uptake across the so-called “outer cell wall” in Gram-negative bacteria and pointed 
towards the potential role of porins in mediating transport25,26. To reduce the number of 
parameters, porins were isolated and reconstituted into artificial planar lipid membranes27,28. 
Conductance measurements suggested single channel pore sizes of about a nm, a value 
surprisingly close to that revealed by high resolution X-ray structures a few years later29. In a 
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different approach, outer membrane porins (OMPs) were reconstituted into multilamellar 
liposomes and kinetic information about transport through the porins was obtained from the 
osmotic swelling induced by successful solute penetration30. These so-called liposome 
swelling assays became an important tool for understanding the uptake of nutrients or 
antibiotics through porins. Initial experiments with this approach, which involved measuring 
the transport of variously sized sugars, established the size exclusion cut-off of the OmpF 
porin to be about 550 Daltons31,32. Ions, amino acids, and small sugars may use general 
diffusion porins to enter the periplasmic space whereas larger sugars and other molecules 
need to use dedicated pathways for outer membrane transport18. These early studies 
established the molecular sieving properties of porins, and provided an explanation for the 
high diffusion rates of these compounds through the outer membrane33. Comparison of the 
diffusion rates of solutes of various sizes gave remarkably reliable values of the channel size 
with respect to the corresponding crystallographic structure. However, swelling occurs in 
response to the movement of all the solutes, including components of the buffer, and 
extreme care is needed when this method is used to study the diffusion of charged solutes31. 
A comparison of some previously available techniques for studying antibiotic permeability 
was also given by Mortimer and Piddock, including the use of the natural autofluorescence 
of quinolones to study their accumulation in a range of bacterial species34.  
 
A number of experimental approaches have thus been utilised to quantify antibiotic 
permeability in Gram-negatives, spanning both precise in vitro techniques for studying 
individual porins or efflux pumps, as well as whole cell screens. However, what is still 
missing is a quantitative technique capable of precisely determining drug accumulation in the 
sub-cellular compartments where their targets are actually located. This is a crucial 
challenge that the field must overcome; controlled studies on individual porins and efflux 
pumps provide invaluable information about the precise routes taken by drugs to enter/exit 
cells, but the extraordinary variety of pathways and proteins in different species make it 
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experimentally unfeasible to study each and every pathway of interest in reconstituted 
systems. Furthermore, there is mounting evidence to show that the expression of these 
proteins is highly dependent on the nutrient microenvironment around the cells35,36. Inherent 
variability in gene expression, especially in efflux pump activity, within an isogenic colony 
leads to variation in drug uptake and hence in drug tolerance24,37. These are all naturally 
occurring complications which confound attempts at understanding drug uptake at the 
(sub)cellular level. It is absolutely critical to develop techniques where cells can be studied in 
their native state, in well controlled microenvironments, rather than after repeated washing 
and resuspension steps in contrived nutrient conditions.  
 
A number of recent reviews have examined the topic of antibiotic accumulation in Gram-
negatives, focussing either on the latest technical developments for quantifying accumulation 
in cells38, summarising what we know about the structure of the cell envelope and the 
challenges associated therein10, or specifically focussing on efflux systems39 and porins40. 
However, we believe that an understanding of this complex problem of antibiotic permeation 
into Gram-negatives will involve insights from both bottom-up biomimetic approaches as well 
as top-down whole cell measurements, and therefore review here the latest techniques in 
both general areas. We will discuss recent whole cell assays based on mass spectrometry 
(MS) and single cell microscopy. However, we will also give an overview of the latest 
developments in electrophysiology measurements of individual transport channels, as well 
as recent liposome based transport assays; these techniques combine biomimetic model 
membranes with microfluidic platforms to study antibiotic transport across lipid bilayers and 
porins with precise control over the drug mixing and exposure times. We will identify the 
advantages and drawbacks of current approaches, and suggest how we might combine 
expertise from different scientific backgrounds to overcome the present technical challenges 
in the field. Finally, we have also included a brief discussion at the end on the economic 
challenges facing antibiotic development, which we feel need to be discussed in the 
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scientific, industrial and regulatory communities in order to ensure that our academic 
investigations do indeed translate into real-world, clinical impact. 
 
Whole cell accumulation assays with Mass Spectrometry 
There have been a number of techniques proposed for measuring antibiotic accumulation 
via MS. Some directly measure the intracellular concentration of the compound, whereas 
others measure the change in the extracellular concentration and use this to determine 
compound accumulation41,42. Figure 2 outlines the general workflow of both approaches. 
Methods measuring the intracellular concentration of the drug are more labour intensive and 
can involve multiple wash stages such as a silicone oil wash23,41,43, centrifugation washes44, 
and filtration processes38,45 to remove the extracellular compound. These wash stages 
potentiate the risk of cell lysis and as such, loss of compound leading to inaccurate results38. 
The silicone oil technique involves layering bacteria that have been incubated with the drug 
over the oil and pelleting it. The silicone oil is then pipetted off along with the supernatant. 
The largest intracellular investigations of accumulation utilised silicone oil to limit 
extracellular binding41,46. This is because, despite the increased manual workload, this 
technique leads to less lysis and a cleaner spectrum due to reduced non-specific binding46. 
The concentration of compounds used in the assays is important; limits of detection restrict 
the use of highly potent antibacterials which, due to the loss of cellular integrity, leak out of 
the cells and thus invalidate the assay23,38. 
 
Richter et al. have progressed intracellular assays to screen up to 180 diverse compounds41. 
They sought to discover and define guidelines for compound permeability. It was revealed 
that in E. coli, molecules which are rigid, flat and possess a primary amine group 
preferentially permeate41.  This study investigated intracellular concentrations through LC-
MS/MS in E. coli MG165541. Richter et al. tested more compounds than have been 
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previously tested, but also examined a broader collection of compounds41. Another 
accumulation study by Davis et al., which involved an LC-MS/MS assay on 10 compounds in 
E. coli, Bacillus subitilis and Mycobacterium smegmatis, struggled to find distinct rules 
governing permeability47. This may be due to the differences in the cell wall and the cell 
membranes of these organisms, or even an environmental parameter, such as growth 
temperature. In addition, the limited diversity of compounds tested also restricted their ability 
to draw conclusions on permeability.  
 
The potential risk of cell lysis due to various assay preparation steps suggests that deducing 
the change in the extracellular concentration of the drug due to cellular accumulation might 
be more useful for high throughput screening42. As outlined in Figure 2, the bacteria that 
have been incubated with the drug are pelleted, following which the supernatant is harvested 
and analysed42. This method requires a minimally permeating cold control to deduce 
accumulation38,42. However, cold controls must also be treated with caution – for instance, 
Stokes et al. showed that cold stress makes E. coli susceptible to glycopeptide antibiotics via 
alterations in the outer membrane48. This demonstrates the challenges of performing 
appropriate controls for accumulation assays in bacteria.     
 
Data generated from these accumulation assays can indicate which compounds accumulate 
in greater concentrations, and as a result are more permeable. This data, however, does not 
resolve accumulation in the various subcellular compartments. There has been some 
progress by Spangler et al. involving the use of click-chemistry and MS to better understand 
subcellular accumulation49. This method has unveiled some useful information about the 
accumulation of a range of drugs which contain an azide group49. However, it is not 
applicable to a large library screening of compounds, as it would require the conjugation of a 
probe to each compound49. An LC-MS/MS study on 132 ligA compounds by Iyer et al. 
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looked at accumulation and on-target activity and reiterated the fact that cytoplasmic 
accumulation is difficult46. Another method used to determine the subcellular localisation of 
drugs is 3D imaging Time of Flight Secondary Ion Mass Spectrometry (ToF-SIMS) by Tian et 
al. Here a cluster ion beam was used to resolve the subcellular localisation of the 
antibiotics50. The C60
+ method of ionisation utilises a label-free method to reveal the 
subcellular localisation of ions with a spatial resolution of approximately 300 nm50. The 
equipment used in this work offers exceptional imaging and spectral analysis of compounds. 
In contrast to standard LC-MS, it is able to combine depth analysis and 2-dimensional 
imaging, making a 3-dimensional molecular rendering feasible50. This technique generates a 
great deal of data as every pixel in the image contains a spectrum. As a result, the data 
analysis is complex, as is the experimental setup itself, and it remains to be seen how easily 
the technique can be transferred into a commercial setting. However, as a label-free 
technique with sub-micron resolution, it represents an important technological advance that 
promises to be a valuable addition to the study of compound accumulation in bacterial 
compartments. 
 
Prochnow et al. have also recently reported a new workflow that involves subcellular 
fractionation via cold osmotic shock, ultrasonic treatment and multiple centrifugation steps to 
quantify the subcellular accumulation of four different classes of antibiotics in WT and efflux 
deficient E. coli cells51. Although the workflow involves multiple steps and hence may not be 
able to examine antibiotic uptake in real time in various environmental conditions, it is 
nevertheless another important advance in the field which enables the measurement of a 
variety of drug classes in a label-free manner directly in the respective vicinities of the drug 
targets. As an example of the information made available, the authors were able to quantify 
differences in the concentrations of ciprofloxacin in the periplasm versus the cytoplasm of E. 
coli; correcting for the volume of the respective compartments revealed that the 
concentration of ciprofloxacin was 6-fold lower in the cytoplasm than in the periplasm. Such 
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quantitative information will be crucial for the rational design of novel drug candidates in the 
next stages of antimicrobial drug discovery. 
 
Despite its many advantages, it is important to note that mass spectrometry generates a 
spectrum which reports the mass to charge ratio of the observed molecule and the intensity 
of ions at this peak, which is not directly quantitative. The determination of concentrations by 
ion intensities can be complicated by contaminants and detergents and as such direct 
quantification of mass spectra is challenging. The current techniques also involve a great 
deal of manual labour, which is incompatible with high throughput screening (HTS). 
Preparing the samples for intracellular accumulation not only includes several cycles of 
centrifugation or silicone oil washing, but also manual lysis methods such as freeze-thaw 
cycles or sonication. To use MS for HTS, techniques such as acoustic mass spectrometry 
have been proposed. This involves using an acoustic dispenser coupled to a mass 
spectrometer52,53. A sound wave hits the sample causing the formation of a droplet which is 
fired into the ionisation beam; this technique can analyse three samples a second52,53. 
Furthermore, the acoustic mass spectrometer is set up in a high throughput 384 well plate 
format, meaning the amount of compound required is greatly reduced52,53. The acoustic 
coupling bypasses  LC-MS loading which increases the speed of analysis, but could mean 
that complex samples are not separated as efficiently52.  
 
A single LC-MS run of one compound generates a vast amount of information, but to 
appropriately deduce accumulation a range of controls are necessary; these include 
measuring signals from the antibiotic with no bacteria, the bacteria with no antibiotic, a non-
permeating control (low temperature, although subject to the caveat about cold controls 
mentioned above), and a high accumulating control (efflux deficient)38.  The sheer amount of 
data generated by these methods suggests the need for machine learning techniques to 
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analyse the data and predict permeability rules. The work by Richter et al. has been 
amalgamated into a website (http://www.entry-way.org/) where the ability of a proposed 
molecule to traverse the outer membrane based on predictive rules can be estimated41. 
Thus MS data is now being utilised for “real-world” output, to show how accumulation data 
can be rationalised into drug design. 
 
Single cell level microscopy  
A number of recent techniques, currently published or under development, involve studying 
antibiotic accumulation at the single-cell level. By combining single cell level uptake 
information with recently developed mathematical models54, there is potential for a 
breakthrough in the field that would enable the prediction of sub-cellular drug localisation 
using model parameters extracted from the experimental data.  
 
Deep UV autofluorescence microscopy and microfluorimetry has been successfully 
implemented by the Pagès group and collaborators to study the accumulation of antibiotics 
in single bacterial cells55–57. These techniques typically involve suspending bacterial cells 
between two quartz coverslips and investigating them with a tunable deep UV light source (a 
synchrotron)58. Bacteria are prepared by culturing them to exponential phase, pelleting them 
via centrifugation followed by resuspension in a NaPi-MgCl2 buffer; the cells are then mixed 
with the compounds of interest just before microscopy58. Using this technique, the group was 
able to study the accumulation of fluoroquinolones label-free in Enterobacteriaceae, 
including studies on cells overexpressing the AcrAB efflux system59. However, the deep UV 
fluorescence measurements require a number of controls for separating cellular 
autofluorescence and crosstalk from the drug signals58. Further, deep UV imaging requires 
quartz optics, including quartz objectives which are not easily available. A number of controls 
for cell viability must also be performed, since deep UV excitation is detrimental for the cells.  
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The same group has also worked with fluorescent derivatives of ceftazidime to study 
intracellular accumulation at the single cell level using microspectrofluorimetry and 
epifluorimetry60. The derivatives accumulated in the periplasm once the outer membrane 
was permeabilised, and periplasmic accumulation was found to correlate with antibiotic 
activity60. However, the authors also noted that modifications of the compounds with 
fluorophores changed the antibiotic activity of the drug in E. coli strains, which needs to be 
accounted for when interpreting permeation rates for fluorescent derivatives.  The Cooper 
and Blaskovich groups (Queensland) have also pioneered the development of a range of 
fluorescent derivatives of antibiotics, which are being applied to single cell level fluorescence 
assays, including using super resolution structured illumination microscopy (SR-SIM)61,62. 
They have recently reviewed the latest developments in the field, showcasing the various 
ways that fluorescent antibiotic derivatives are being used to investigate mechanisms of 
resistance63. 
 
However, techniques based on single cell fluorescence still, in general, lack the ability to 
resolve accumulation in subcellular compartments. As mentioned previously in relation to 
MS approaches, centrifugation and washing steps are less than ideal, and yet without them, 
it is challenging from single cell microscopy to distinguish drug molecules bound to the outer 
membrane from drug molecules that actually permeate into the cell. What is also missing is 
the development of accumulation assays in which the microenvironment and the drug 
exposure time is well controlled – this is where nanofluidic or microfluidic techniques could 
provide solutions. Indeed, a nanofluidics assay, combining bacterial trapping in 
microchannels with controlled drug exposure, was recently reported by the Lee group; they 
quantified the translocation of clindamycin through wild-type and an efflux deficient E. coli 
strain, although they used an LCMS assay to quantify the clindamycin flux per cell rather 
than a fluorescence readout64. However, although the calculation is performed “per cell”, the 
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actual measurement accumulates perfusion data across a population of approximately 200 
cells. Further, the technique measures the flux of drug molecules across the cell rather than 
cellular accumulation itself, and it is unclear whether any subcellular concentration 
information can be inferred from this technique. The technique also relies on having an 
excellent seal between the cells and the trap channels, which may limit its applicability – 
different cell types and even isogenic cells in different metabolic states will have different 
widths and shapes, which would affect the quality of the seals and lead to leakage of the 
drug molecules between the loading and collection channels. Nevertheless, combining 
innovative microfabrication and single cell trapping approaches37 with microfluorimetry or 
fluorescence has the potential to enable measurements of drug accumulation in well-defined 
microenvironments. This is important when considering that different growth conditions lead 
to changes in porin expression35; these systems could be used to analyse the role of 
different media conditions in influencing drug accumulation kinetics.  These assays are 
currently under development, and combining microfluidics with the latest microscopy 
techniques has immense potential for solving long standing problems in the field.  
 
Raman microscopy and microspectroscopy have also been used to study the uptake and 
interactions of -lactamase inhibitors in groups of freeze-dried E. coli cells65,66 in a label-free 
manner. The Carey group built upon their expertise in detecting different inhibitor-enzyme 
intermediates with Raman microscopy67 to study the penetration of clavulanic acid and 
tazobactam into E. coli cells; their inhibitory effects on -lactamases were also 
characterised65. Although Raman spectroscopy has in the past been technically challenging 
when used to study bacteria due to low signals and noisy backgrounds, the use of freeze-
drying and subsequent difference spectroscopy has now enabled these semi-quantitative 
measurements in groups of cells66. 
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Alternative techniques to measure uptake in cells involve using enzymatic activity inside 
the bacteria as a readout. For example, the influx of cephalosporins can be measured by 
coupling their uptake to their hydrolysis by periplasmic β-lactamases68–70. However, to 
connect whole cell experiments with single channel recordings, it is important to be able to 
quantify the amount of functional protein in the outer membrane. Recently the team of D. 
Bumann at Biozentrum Basel was able to quantify the number of porins in the outer 
membrane of Acinetobacter baumanii in infected mouse and rat lung tissue71.  Combining 
new techniques for single cell level uptake measurements with developments in proteomics 
would be extremely beneficial for the field, although at present there remain significant 
technical challenges that still need to be overcome before this can be made a reality. 
 
Latest developments in electrophysiology: 
Molecular details of antibiotic transport through specific porin pathways can be obtained 
from single channel characterisation experiments in “black lipid membranes” or “BLMs”, 
which are described in detail in Gutsmann et al.72. Briefly, purified detergent-solubilised 
channel proteins or proteoliposomes are added to one side of the membrane and 
spontaneously insert into the bilayer over time. The sequential insertions of open channels in 
the membrane lead to discrete current jumps due to ion movement through the open 
channels. The conductance (i.e., the amount of current per unit voltage) of a channel can be 
obtained by measuring the size of these current jumps. For a number of applications, the 
reconstitution of proteins into giant unilamellar vesicles and subsequent patch–clamp 
measurements are advantageous73. For this technique, a commercial tool (Port-a-Patch, 
Nanion Technologies) may be used, which facilitates the experimental handling as the 
liposome containing preparation is simply pipetted on top of a hole in glass and aspirated to 
form a giga-seal74,75. After insertion, the channel activity can be studied under various 
conditions (e.g. in the presence of DNA, polymers or small molecules). Investigations by the 
Benz and Rosenbusch groups in the ‘70s and ‘80s established some of the hallmark 
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properties of the general diffusion porins, such as the relatively large pore size, low ionic 
selectivity and high opening probability75–77.  
The main advantage of BLM measurements is their ease of access and the low 
consumption of protein. Although this is a single molecule technique, the information 
originates from the modulation of the ion current with time; the extracted information is an 
average over the entire path along the channel. More molecular details about how the 
molecules move along the channel and their main point of interaction can be obtained in 
combination with all atom molecular dynamics (MD). Indeed, with the numerous high 
resolution structures upcoming forthwith, MD simulation is a perfect complementary 
technique to single channel electrophysiology. For example, some years ago the ion 
pathways in OmpF were investigated in more detail, and these studies revealed that the 
paths taken by anions and cations are divergent at the constriction region (CR); cations are 
drawn close to the negative charges of the L3 loop, and anions flow near the positively 
charged cluster of the opposite barrel wall (see also Figure 3a)78–80. This type of work 
emphasises the notion that the permeating ions interact with the wall of the channel and that 
ion movement does not follow simple diffusion. Moreover, measuring the temperature 
dependent OmpF channel conductance and normalising over the temperature dependent 
bulk ion conductances revealed a clear deviation from the bulk. An Arrhenius plot allows the 
quantification of these ion interactions79,80. MD modelling revealed two distinct ion pathways 
when the ion concentration is below 150 mM KCl, whereas above this concentration, ions fill 
almost the entire pore volume.79,80  
 
In a similar manner, substrate permeation is facilitated by an affinity to specific channels. 
The addition of malto-oligosaccharides to LamB (Maltoporin) from E. coli drives the sugar to 
enter the binding site and block the channel entirely for ions. The occupancy of the binding 
site with sugar was obtained by measuring the reduction in channel conductance81. The 
permeabilities obtained for malto-oligosaccharides using ion current noise agreed well with 
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liposome swelling results, except in the case of sucrose30,81. Inspection of the structure 
revealed that sucrose has a binding site but is not able to permeate82. It is also possible to 
extend the noise analysis technique to antibiotic permeation. However the analysis requires 
a sufficiently strong binding of the drug to the channel, and the antibiotic in the binding site 
must sufficiently block the ion current83. A further point to note is the inherent instability of 
antibiotics84. For example, in the case of ampicillin, a short exposure to basic pH to enhance 
the solubility can degrade large amounts of the compound.  
 
Binding can be distinguished from transport by applying an external force on charged 
molecules. As such, an electric field can drag or repel charged permeating molecules, which 
is then translated into a modification of the residence time in the channel. Thus, measuring 
the average translocation time for different external electric fields should provide a clear 
picture85. In the case of uncharged molecules, the molecular movement could be modulated 
by electro-osmotic flow86. Most of the porin channels have an excess of one charge species 
in the constriction zone, thus an externally applied electric field would cause a net 
unidirectional incoming flow; molecules diffusing with the flow would have shorter residence 
times (see Figure 3b). In a series of investigations, the specific permeation of α-cyclodextrin 
across CymA of Klebsiella oxytoca was quantified; the individual steps have also been 
simulated86. A more recent suggestion for enhancing the signal for translocation is to 
engineer a barrier for exit within the pore87. By comparing the residence times of molecules 
in the porin in the presence and absence of the barrier on the periplasmic side of the 
channel, one can identify true permeation events and identify molecules that reach the exit. 
Starting from the well-studied porin OmpF, a single point mutation at position 181 OmpFE181C 
was introduced and crosslinked with either Sodium (2-sulfonatoethyl) MethaneThioSulfonate 
(MTSES) or glutathione. The modification of OmpFE181C by MTSES builds a barrier which is 
sufficient to block the pathway of norfloxacin through the porin. The modulation of the 
interaction dwell time allows one to determine the successful permeation of norfloxacin 
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across wild-type OmpF. This approach might enable the discrimination of blockage events 
from translocation events for a wide range of substrates while working in the µM range. As 
the data analysis is straightforward, parallelisation of the experiments might be possible. A 
potential application of this technique could include screening for molecular structures to 
improve the permeability of antibiotics. 
 
A different approach involves the use of an unbalanced charge accumulation84,88. 
Creating a concentration gradient between both sides of the channel induces a 
concentration driven flux (see Figure 3c). In most cases, one of the ions diffuses slower than 
the counter ion; the difference in flux creates a diffusion potential. Measuring the diffusion 
potential as a function of the concentration gradient reveals relative fluxes. In combination 
with a single channel conductance measurement, a more quantitative analysis is possible. 
Note that the cation’s permeation strongly depends on that of the anion and vice-versa and 
thus the permeability is not a simple constant but varies with concentration and the 
counterions. In the case of charged antibiotic molecules, their channel permeability can be 
estimated by the application of a concentration gradient and the measurement of the 
potential built up by an unequal permeation of the cation versus the anion. This technique is 
similar to a selectivity measurement, and a numerical solution based on the Goldman-
Hodgkin-Katz ion current equation can be used. The permeation of three β-lactamase 
inhibitors (avibactam, sulbactam and tazobactam) through OmpF and OmpC orthologues 
from four enterobacterial species was recently characterised using this approach. The 
information from electrophysiology can be combined with existing high resolution structures 
and modelling to obtain the energy barrier. For example, in the case of OmpF, the energy 
barrier for small ions is low and broad whereas for the beta-lactam inhibitors the barrier is 
substantially higher and narrower (see Figure 3d). Surprisingly there is also a shallow affinity 
site just before the entry at the extracellular side88. Well-designed single channel 
conductance measurements, in combination with MD simulations, thus continue to be a 
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powerful tool for investigating transport through individual components of the bacterial cell 
envelope at the molecular level. 
 
 
Biomimetic liposome assays: 
Liposomes or lipid vesicles are versatile tools for studying membrane processes89. We have 
already discussed how multilamellar (multiple lipid bilayers) liposomes were used in swelling 
assays to study solute transport through porins. On the other hand, unilamellar vesicles 
containing a single lipid bilayer can be used to mimic the lipid bilayer of cell membranes, with 
precise control of the lipid content and composition of the membrane. Small unilamellar 
vesicles (SUVs) typically have diameters between 50 – 200 nm, large unilamellar vesicles 
(LUVs) range from 200 – 1000 nm in diameter, whereas giant unilamellar vesicles (GUVs) 
typically have diameters ranging from 1 – 100 m.  SUVs and LUVs can be formed relatively 
easily and quickly using lipid extrusion techniques90, and are then often subjected to bulk 
assays such as spectrofluorimetry where transport or binding processes are studied using 
changes in the fluorescence or absorbance of the bulk solution as a whole over time91. This 
is typically correlated with the leakage of a dye or fluorophore encapsulated within the 
vesicles, or alternatively, the transport of a solute across the SUV bilayers which then reacts 
with an encapsulated target to change the fluorescence of the solution92. The latter principle 
was combined with TIRF microscopy and microfluidics by the Dittrich group to study 
tetracycline transport across SUV membranes, where the SUVs were immobilized on a glass 
substrate via an avidin-biotin bond93. The process involved encapsulating an Eu3+ salt inside 
the vesicles, which formed a fluorescent complex with tetracycline as it diffused across the 
SUV bilayers93. They used the technique to investigate the influence of membrane 
composition on permeation rates, and showed that although drug lipophilicity as predicted by 
traditional octanol-water partition coefficients correlates well with membrane permeability, it 
is not the only significant parameter93.  
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Similar results were observed with a related approach, developed in the Keyser laboratory at 
the University of Cambridge, where GUVs were used as the model membranes. The 
advantage of using GUVs is that membrane transport can be investigated at the single 
vesicle level using standard microscopy approaches94. However, traditional techniques using 
GUVs are limited in throughput – the GUVs are typically suspended in a droplet on a 
coverslip, and when fluorescent compounds are added, their uptake is measured by 
studying the change in fluorescence inside the GUVs. However, this is limited in throughput 
to the number of vesicles in the field of view of the microscope95. The other problem with 
such experiments is that the initial time of drug arrival and its concentration in the vicinity of 
the GUVs are both ill defined. 
 
These technical problems were overcome using microfluidics. The GUVs were formed off 
chip using electroformation96, and were then introduced into one of the inlets of a simple T-
junction microfluidic device, whose channels were approximately 40 m in width and 
height97,98. The drug of interest was added using the second inlet of the T-junction, and the 
flows were controlled by applying suction at the outlet using a syringe pump97. The design 
enables the equal mixing of the vesicle fluid stream with the antibiotic at the T junction, and 
thus the time of vesicle exposure to the drug as well as the drug concentration surrounding 
the vesicle are both well defined97. The use of a flow system enabled measurements on 
hundreds of vesicles rather than the tens of GUVs normally studied in such assays94,95. 
Importantly, the technique utilised the autofluorescence of quinolone antibiotics in the 
ultraviolet (ex = 340 nm) to track their uptake in GUVs label-free; this simplifies the analysis 
since there are no secondary binding interactions that need to be accounted for when 
calculating the accumulation of the drug in the GUVs.  Furthermore, unlike the industry 
standard PAMPA (parallel artificial membrane permeability assay) technique, there are no 
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significant complications from unstirred water layers98, which may affect the interpretation of 
compound permeability99.  
 
Using this technique, the group also confirmed that lipid composition plays a critical role in 
antibiotic permeability100. For example, at pH 7, norfloxacin permeability was found to be an 
order of magnitude higher for GUVs made of DOPC lipids as compared to DPhPC – these 
lipids have the same phosphatidylcholine (PC) head-groups but differ in the composition of 
their hydrocarbon tails, with the branched methyl groups in the DPhPC tail believed to be 
responsible for its lower permeability to small molecules100. The group investigated 
norfloxacin transport across GUV membranes formed from a range of different lipid mixtures, 
and further reiterated the need to quantify drug transport across the specific lipid bilayer 
composition of interest100.  
 
Such investigations will also be particularly important for comparing the permeation of drugs 
across Gram-positive membranes and the cytoplasmic membrane of Gram-negatives. There 
is some debate in the field about the relevance of the cytoplasmic membrane of Gram-
negatives as a barrier, since a wide range of drugs are able to accumulate in the cytoplasm 
of, for instance, E. coli cells with compromised outer membranes101. However, as mentioned 
in the introduction, the difficulty with Gram-negative cytoplasmic entry arises from the 
apparently orthogonal sieving properties of the outer versus the cytoplasmic membrane, as 
has been extensively discussed previously10,101. It is also worth noting that Gram-positive 
membranes and the cytoplasmic membranes of Gram-negatives differ significantly in their 
lipid compositions102. This is likely to lead to quantifiable differences in drug transport rates 
across these membranes, which should be a future avenue for liposome based 
investigations. 
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Vesicles are thus good models for studying passive transport across the cytoplasmic 
membrane of bacteria, where solubility and diffusion across the lipid bilayer are important. 
However, transport across the outer membrane is generally governed by the porins. We 
have reviewed electrophysiology approaches to study antibiotic binding and transport 
through individual porins in a separate section. However, although these measurements 
have proved invaluable in understanding the molecular interactions between different drugs 
and channels, they are limited by the fact that actual fluxes are still challenging to measure.  
 
To solve this conundrum, the authors (JC and MW) collaborated to reconstitute OmpF into 
GUV membranes, creating proteoliposomes which could then be studied in the microfluidic 
transport assay described above (Figure 4)103. This provides a controlled, bottom-up 
approach to studying antibiotic transport across biomimetic bacterial membranes – 
norfloxacin transport was first quantified across pure GUV lipid membranes, and then the 
same experiments were performed with the OmpF containing proteoliposomes. The 
experiments directly measured the enhancement in flux due to the porins in the membrane, 
paving the way for quantifying antibiotic permeability through transport proteins of interest 
using a direct optical readout103.  
 
A difficulty with GUV based approaches has been that traditional vesicle formation protocols 
have a number of limitations. Electroformation, for example, involves applying alternating 
electric fields to bud lipid films off a conducting surface – this makes the use of physiological 
salt conditions challenging104. The populations also contain vesicles of varying diameters, 
and there are often difficulties associated with batch-to-batch variability, especially in the 
presence of salts. Furthermore, there are various reconstitution techniques for incorporating 
proteins in GUVs, but they each have certain drawbacks and there is no one standard 
technique that works better than the rest105.  In order to overcome these challenges, a 
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number of groups have now developed microfluidic GUV formation protocols106. One 
promising technique is octanol-assisted liposome assembly (OLA), developed by the Dekker 
group in Delft107. This involves a microfluidic jetting technique where lipids are dissolved in 
octanol as the organic phase – post GUV formation, the octanol forms a pocket which then 
spontaneously buds off as a droplet. The octanol can be separated108 and then the pure 
GUVs analysed downstream of formation.  We have now successfully integrated the OLA 
platform with an antibiotic transport assay downstream of GUV formation, thus providing a 
complete lab-on-chip platform to create and test vesicles in physiological salt conditions109.  
 
These new microfluidic liposome formation platforms will also enable the investigation of an 
important question with regards to the transport of charged molecules across cytoplasmic 
membranes. As mentioned previously, the challenge with Gram-negative cytoplasmic uptake 
is that charged, hydrophilic molecules preferentially permeate the outer membrane, but then 
face a hydrophobic cytoplasmic lipid membrane across which their transport rates are much 
slower than that of neutral uncharged species; this has been quantified directly for drugs in 
different charge states98. It has been proposed that the transport of charged molecules 
across the cytoplasmic membrane may be mediated by the proton motive force and 
electrochemical gradients, leading to energy-dependent but carrier- independent 
mechanisms of transport10. In the past, membrane vesicles from species such as 
Lactococcus lactis and Leuconostoc mesenteroides have been coupled with membrane 
potentials to examine the transport of amino acids, citrate and malate110,111, but detailed 
investigations on antibiotic uptake in such conditions have not yet been realised. Using the 
OLA formation platform, we have recently demonstrated that it is possible to trap thousands 
of vesicles encapsulating a pH sensitive dye in physical traps112; the vesicles are then 
subjected to antibiotic treatment over a time period of hours. This platform could in the future 
be utilised to study the role of electrochemical and pH gradients on drug transport by utilising 
the high encapsulation efficiency of the OLA platform. One could potentially set up precise 
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electrochemical and pH gradients between the interior and the exterior of these synthetic 
vesicles and then flush charged antibiotics into the system, monitoring the uptake of the 
drugs via a fluorescence based readout similar to that described above. Such investigations 
could be used to quantify the role of electrochemical potentials on the uptake of charged 
antibiotics across model cytoplasmic membranes. 
 
Vesicles are therefore promising model systems for the study of passive antibiotic transport 
across specific lipid and porin pathways in bacteria. However, they have also been used to 
study active efflux via the reconstitution of bacterial efflux systems in proteoliposomes113. 
The LmrP multidrug transporter from Lactococcus lactis was successfully incorporated in a 
proteoliposome system by the van Veen group in Cambridge, where it was used to study 
Calcium transport113. Complexes of OprM and MexA, two proteins from the MexA-MexB-
OprM multidrug efflux pump of Pseudomonas aeruginosa have also been reconstituted in 
SUVs and LUVs for the cryo-electron tomography of the protein complexes, suggesting that 
entire MDR efflux pump complexes can be successfully reconstituted114. The Picard group 
combined proteoliposomes containing the MexAB and the OprM parts of the complex to 
develop an assay that measured energy-dependent substrate transport in a system 
designed to mimic the Gram-negative double membrane115. The authors proposed that their 
model system be used to screen for inhibitors of the efflux pump, which would be valuable 
assets for restoring the activity of older antibiotics that would otherwise be subjected to efflux 
from the cell115.  
 
Protein reconstitution in SUVs or in multilamellar vesicles has traditionally been far easier 
than reconstitution in GUVs. Therefore, techniques to form GUV sized proteoliposomes from 
SUV proteoliposomes are of great interest, enabling the screening of multiple different 
bacterial transport proteins using the modern microfluidics approaches described above. The 
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Spatz group has recently published a technique116 that uses SUVs encapsulated in block-
copolymer surfactant-stabilized water-in-oil droplets; by tuning the charge at the inner 
interface of the droplet, SUVs can be made to adsorb at the interface forming droplet-
stabilized (ds) GUVs. They demonstrated a simple step to release these GUVs from the 
surfactant and oil, resulting in a high yield of GUV formation116. This paves the way for 
converting SUV-proteoliposomes into GUV-proteoliposomes which could then be 
investigated as described above, with high resolution microscopy/microfluidics approaches.  
 
Both OLA and the dsGUV techniques are relatively recent developments in the field, and 
hold great promise for the construction of truly biomimetic models of bacterial membranes. 
The next technical leap would involve the controlled formation of double bilayers to better 
mimic Gram-negative cell envelopes. If this were to be achieved, it is not inconceivable to 
imagine the reconstitution of entire transporter complexes such as MDR efflux pumps, 
spanning the “inner” bilayer, the “periplasmic” inter-membrane space and the “outer” bilayer, 
in these model systems. By subjecting them to the antibiotic transport measurements 
described above, a wealth of information could be untapped regarding the fluxes, activation 
barriers and selectivity of these crucial antibiotic transport pathways in bacteria.  
 
A note on the economics of antibiotic research and development:  
We end this review with a slight diversion from our topic of studying transport across 
bacterial membranes. As professional scientists, it is sometimes easy to lose track of the 
bigger picture when working on the technical minutiae of a problem. Why are we interested 
in understanding the details of antibiotic transport? Obviously, the major aim is to exploit our 
knowledge and techniques to develop more effective antibiotics and to circumvent existing 
drug resistance and tolerance mechanisms. However, to translate this work into antibiotic 
development and ultimately, to the benefit of actual patients, we require a drug development 
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ecosystem whereby promising academic discoveries are implemented in a timely and 
effective manner in biotechnology and pharmaceutical companies.  
 
However, as the field knows very well, the antibiotic pipeline has dried up – no new broad 
spectrum antibiotic classes have been brought to the market in the past 5 decades117.  This 
is not only a scientific but also an economic problem, as has been recognised by numerous 
studies on the issue1,2,118,119. In a volume-based payment system, revenues are driven by 
sales, sales are driven by prescriptions; but with antibiotics, the more prescriptions there are, 
the faster resistance develops, thereby lowering the intrinsic value of the drug120. New 
antibiotics typically need to be preserved for last-resort cases in which all other options have 
been exhausted, which also translates to lower sales. Even extremely promising drug 
candidates such as Novartis’ new monobactam derivative LYS228 are currently being pulled 
from the pipeline, with the company seeking to outlicense the therapeutic121. Unless the 
economic challenges are resolved, irrespective of the scientific advances made in 
understanding the basic biology and pharmacokinetics, real world impact in clinics will not be 
observed.  
 
In his seminal review of the field, Lord O’Neill stressed the importance of tackling this 
antibiotic development and supply problem1. Both he and others120,121 have suggested giving 
market entry rewards of the order of $1 Billion to the developers of new antibiotics, to both 
develop and actually manufacture stocks of new antibiotics which would be made available 
in clinical settings as appropriate. It is pertinent here to stress the importance of 
manufacturing and maintaining stock supplies, even if the drugs are used sparingly; it is 
worrying to note that economic considerations are leading to supply failures of commonly 
prescribed antibiotics in today’s market, further exacerbating problems in infectious disease 
control122. Market entry rewards need participation from various governments, to tackle what 
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is very much a global problem – pathogens do not recognise passport controls. A global 
antibiotics reward fund, sponsored by the World’s major economies, would be able to 
address this issue. Along these lines, it is heartening to note that the UK government has, in 
January 2019, announced a 20-year vision and a 5-year national action plan on antimicrobial 
resistance, which includes proposals to address the antibiotic market failure crisis and 
incentivise antibiotic development123.  
 
Besides governments, it is also worth considering the massive public and charitable 
engagement that other fields of medical research have generated, and contrast that with the 
case of antibiotic research. In 2017-18, Cancer Research UK raised £634 Million124. The 
British Heart Foundation raised £159 Million in 2016-17125. In contrast, Antibiotics Research 
UK, the only charity in the World focusing specifically on antimicrobial resistance, had an 
income of £235,000 in 2016-17126, three orders of magnitude lower than the others. These 
figures show just how much scope there is to increase funding for this crucial area of 
research through public engagement. Public awareness and charity involvement would 
boost basic research into antibiotics, which would help refresh the development pipeline and 
potentially lower entry barriers for pharmaceutical companies looking to enter or re-enter the 
field. We urge the scientific community, policy makers, heads of charitable organisations and 
the general public across the globe to consider these issues seriously and begin planning 
ways to massively increase funding to this vital sector, both in the areas of basic research 
such as the transport studies discussed here, as well as in the translational programmes 
involved in getting new drugs from the bench into the clinic.  
 
Concluding remarks: 
Despite the challenging economic environment for antibiotic R&D in general, research into 
drug permeation in bacteria has developed considerably over the past decade. These new 
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techniques will pave the way for identifying and characterising the physicochemical 
properties of permeating compounds, which should help guide medicinal chemists in their 
quest for discovering novel antimicrobials with Gram-negative activity. The various 
methodological innovations involving mass spectrometry, fluorimetry and microfluidic assays 
also offer new opportunities to better understand the relationships between genetic control of 
the transport pathways and bacterial adaptation to diverse environmental stresses. Real-
time measurements of the intrabacterial accumulation of specific molecules, inducers, 
inhibitors and antimicrobial drugs represent important breakthroughs which have been made 
possible by collaborations extending across traditional scientific boundaries. Recent 
developments in whole cell assays, using MS and single cell microscopy, have been vital to 
the field and show great promise in providing crucial information for the rational design of 
new antibiotics. Complementary research programmes with continuous feedback between 
the whole cell and model system based transport assays will be crucial for generating a 
holistic understanding of transport in these systems. Such programmes will require 
molecular biologists, microbiologists, geneticists, medicinal chemists, biophysicists, 
mathematical modellers, bio-engineers and image analysis experts to succeed. Although the 
problem is extremely complex, the recent developments reviewed here suggest that, with the 
right scientific networks and funding modalities, a more fundamental understanding of drug 
permeation in Gram-negatives is accessible. This will be invaluable in the search for new 
drugs to tackle the next generation of resistant pathogens.   
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Figure 1. Schematic of the Gram-negative cell envelope. Adapted with permission from 
Manchester, J. I., Buurman, E. T., Bisacchi, G. S. and McLaughlin, R. E. “Molecular 
determinants of AcrB-mediated bacterial efflux implications for drug discovery.” J. Med. 
Chem. 55, 2532–2537 (2012). Copyright (2012) American Chemical Society. 
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Figure 2. General workflow of Mass Spectrometry assays. An outline of the general 
workflow utilised in mass spectrometry based intracellular and extracellular drug 
concentration measurements. 
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Figure 3(a). Iso-density surfaces of the Cl-  (left) and K+ ion densities (right) in an 
OmpF channel averaged over the full trajectory.  The important residues in the 
constriction zone are shown as well.  For details, please see Pezeshki et al. (2009)80. 
Reprinted from Biophysical Journal Vol. 97, Soroosh Pezeshki, Catalin Chimerel, Andrey N. 
Bessonov, Mathias Winterhalter and Ulrich Kleinekathöfer, “Understanding Ion Conductance 
on a Molecular Level: An All-Atom Modeling of the Bacterial Porin OmpF”, pages 1898-1906. 
Copyright (2009), with permission from Elsevier. 
(b). Effect of electroosmotic flow. Typical ion-current recordings at positive voltage +100 
mV (top) and negative voltage −100 mV (bottom) in the presence of 10 μM α-CD on the 
extracellular side of CymA in 1 M KCl.  Here, the electroosmotic flow drags the neutral α-CD 
into the channel and briefly blocks the ion current through the channel. Reversing the 
voltage reverses the flow direction and only a few α-CD molecules reach the channel, with 
substantially shorter residence times. Variation of the applied external transmembrane 
voltage will modulate the residence times and allows one to determine whether or not 
translocation was successful86. Reprinted from Biophysical Journal Vol. 110, Satya 
Prathyusha Bhamidimarri, Jigneshkumar Dahyabhai Prajapati, Bert van den Berg, Mathias 
Winterhalter and Ulrich Kleinekathöfer, “Role of Electroosmosis in the Permeation of Neutral 
Molecules: CymA and Cyclodextrin as an Example”, pages 600-611. Copyright (2016), with 
permission from Elsevier. 
(c). For charged molecules, a concentration gradient can be applied driving cations 
and anions through the channel. A difference in the electrophoretic mobility causes a 
diffusion potential and allows one to identify translocation, and to distinguish translocation 
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events from binding. Combining this with single channel recordings allows one to estimate 
the flux.  
(d). All atom modelling performed in the group of M. Ceccarelli shows the energy barrier 
for translocation. OmpF as a cation selective channel has a low and broad barrier for K+ and 
a higher one for Cl-. In contrast, beta-lactam inhibitors like Avibactam, Sulbactam or 
Tazobactam have sharp energy barriers88. Reprinted in part with permission from Ghai, I., 
Pira, A., Scorciapino M. A., Bodrenko, I., Benier, L., Ceccarelli, M., Winterhalter, M. and 
Wagner, R., “General Method to Determine the Flux of Charged Molecules through 
Nanopores Applied to β-Lactamase Inhibitors and OmpF”. J. Phys. Chem. Lett. 8, 1295–
1301 (2017). Copyright (2017) American Chemical Society. 
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Figure 4. Schematic of proteoliposome based microfluidic assays for studying 
antibiotic transport across biomimetic membranes. Liposomes and OmpF embedded 
proteoliposome model membranes are mixed with an autofluorescent antibiotic (norfloxacin, 
ex = 340 nm) in a T-junction microfluidic device. As the control liposomes (a) or 
proteoliposomes (b) move through the bath of the drug, they accumulate the drug at different 
rates. Video fluorescence microscopy at multiple time points is used to determine the 
permeability coefficient of the drug crossing the model membranes. The difference in the 
permeabilities of the liposomes and proteoliposomes to the drug is used to quantify antibiotic 
flux through the porins in the proteoliposome membranes. The number of porins per 
proteoliposome is quantified separately using electrophysiology. Figure reprinted with 
permission from Cama, J., Bajaj, H., Pagliara, S., Maier, T., Braun, Y., Winterhalter, M. and 
Keyser, U. F. “Quantification of Fluoroquinolone Uptake through the Outer Membrane 
Channel OmpF of Escherichia coli.” J. Am. Chem. Soc. 137, 13836–13843 (2015). Copyight 
(2015) American Chemical Society. 
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